DUBLIN, Ireland and SAN ANTONIO, Texas, May 13, 2026
ICON plc announced a major expansion of its U.S. early phase clinical research infrastructure with the launch of a new 69,500-square-foot Clinical Research Unit (CRU) in San Antonio, Texas, alongside two new satellite outpatient clinics in Houston, Texas, and Lawrence, Kansas. The expansion significantly strengthens ICON’s capabilities in conducting first-in-human studies, healthy volunteer trials, and patient cohort research, while improving participant accessibility and accelerating clinical development timelines.
ICON Launches Advanced Clinical Research Unit in Texas
The newly opened San Antonio CRU has been purpose-built to integrate clinical operations, laboratory services, investigational pharmacy infrastructure, and sample processing under a single roof. According to ICON plc, the fully integrated design is intended to eliminate operational bottlenecks commonly associated with fragmented early phase research environments.
The facility includes a Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP)-compliant pharmacy, advanced investigational product handling capabilities, and ISO-certified cleanrooms designed to support complex dosing and manufacturing requirements. Additional onsite infrastructure includes a clinical safety laboratory, specimen processing and shipping systems, and dedicated monitoring technology that enables rapid clinical response and real-time patient observation.
By centralizing pharmacy, laboratory, and clinical functions, ICON stated that sponsors can benefit from faster dosing schedules, immediate protocol adjustments, and accelerated data delivery, helping improve study efficiency and reduce delays during early-stage development programs.
The company also emphasized patient-focused design within the new facility. The San Antonio site includes private and semi-private dormitories, recreation spaces, enhanced safety systems, and dedicated participant care areas, supporting both comfort and retention during extended study participation.
Advertisement
Satellite Clinics Expand Recruitment and Participant Access
In addition to the flagship San Antonio facility, ICON has opened two new outpatient research centers in Houston, Texas, and Lawrence, Kansas. These satellite clinics are designed to expand participant recruitment reach while reducing the travel burden associated with Phase I clinical trials and long-term follow-up visits.
Dr. Ute Berger, Chief Medical Officer and President of Development Solutions at ICON, stated that the integrated infrastructure was specifically designed to improve participant experience while simultaneously increasing operational scalability and maintaining high-quality research standards. She noted that the elimination of logistical delays through co-located services enables more adaptable clinical operations and faster delivery of high-quality trial data for pharmaceutical and biotechnology sponsors.
ICON Strengthens Global Early Phase Research Strategy
The new San Antonio CRU joins ICON’s expanding global network of dedicated Phase I research facilities, which already includes locations in Salt Lake City, Utah; Lenexa, Kansas; Groningen, Netherlands; and Budapest, Hungary. The company said the latest investment reinforces its long-term strategy to strengthen early phase development capabilities amid rising global demand for faster and more efficient clinical trial execution.
ICON plc is one of the world’s largest clinical research organizations, providing consulting, development, commercialization, and post-marketing services to pharmaceutical, biotechnology, medical device, and public health organizations worldwide. As of the end of 2025, the company employed approximately 40,100 employees across 97 locations in 55 countries.
The continued expansion of ICON’s infrastructure highlights growing industry investment in integrated early phase research environments capable of supporting increasingly complex therapeutic pipelines while improving both sponsor efficiency and patient engagement.
Source: ICON plc press release
